Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome
Centre Hospitalier Universitaire de Saint Etienne
60 participants
Jul 2, 2025
INTERVENTIONAL
Conditions
Summary
Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a common and serious neurological complication associated with the use of CAR-T cells. The mechanisms involved are still poorly understood but studies suggest that inflammation during treatment leads to an increase in the permeability of the barrier between the brain and the blood vessels and the emission of extracellular vesicles (EVs) circulating between the brain and the blood vessels. EVs are biological particles that play an important role in cellular communication and the modulation of several physiological processes. The VESICANS study aims to characterize the EVs released before and during CAR-T cells treatment and upon the occurrence of ICANS, using flow cytometry, electron microscopy, Nanoparticle Tracking Analysis associated with MRI assessment of the barrier between the brain and blood. This study will ultimately contribute to facilitating the prevention and treatment of this toxicity which affects the prognosis of patients.
Eligibility
Inclusion Criteria4
- Patient aged over 18,
- Patient for whom CAR-T treatment is indicated,
- Patient affiliated to a social security system
- Patient who give his consent to participate in the study.
Exclusion Criteria3
- Pregnant or breastfeeding woman,
- Patient unable to understand informed consent,
- Patient under legal protection.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Biological tests : cell quantification et characterization
MRI
Neuropsychological tests
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06706102